Announcing the Intent To Award a Single-Source Supplement for the Alternatives to Guardianship Youth Resource Center Cooperative Agreement, 62089-62090 [2023-19391]
Download as PDF
<![CDATA[
Federal Register / Vol. 88, No. 173 / Friday, September 8, 2023 / Notices
for the Treatment of Alzheimer’s
Disease; Use: CMS Office of Minority
Health (OMH) is going to announce a
call for nominations for the 2024 CMS
Health Equity Award. This award will
recognize organizations who
demonstrate they have advanced health
equity by designing, implementing, and
operationalizing policies and programs
that support health for all the people
served by our programs, reducing
avoidable differences in health
outcomes experienced by people who
are underserved, and provided the care
and support that CMS enrollees need to
thrive.
The goals of the award are to
encourage organizations to identify and
address their health disparities, to
disseminate best practices, and to show
that progress is possible by having a
results-oriented focus. By identifying
organizations who are successfully
closing gaps and reducing disparities,
CMS can show our stakeholders how
health equity work can be initiated,
targeted, measured, and successfully
reduce disparities among communities
nationwide.
CMS Representatives collect
Company Name, Point of Contact
Information (email, phone# & name)
along with information from the
organizations regarding their programs
to improve the health quality, outcomes,
and access to care for the communities
that they serve. The CMS selection
committee uses a scoring rubric to score
the applicants on demonstrated
measurable results in reducing a
disparity in one or more of the CMS
priority populations. Form Number:
CMS–10866 (OMB control number:
0938–NEW); Frequency: Annually;
Affected Public: Federal Government,
Business or other for-profits and Notfor-profit institutions; Number of
Respondents: 50; Number of Responses:
50; Total Annual Hours: 100. (For
policy questions regarding this
collection, contact Ashley PeddicordAustin at 410–786–0757.)
lotter on DSK11XQN23PROD with NOTICES1
Dated: September 1, 2023.
William N. Parham, III,
Director, Paperwork Reduction Staff, Office
of Strategic Operations and Regulatory
Affairs.
[FR Doc. 2023–19359 Filed 9–7–23; 8:45 am]
BILLING CODE 4120–01–P
VerDate Sep<11>2014
17:30 Sep 07, 2023
Jkt 259001
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Administration for Community Living
Announcing the Intent To Award a
Single-Source Supplement for the
Alternatives to Guardianship Youth
Resource Center Cooperative
Agreement
ACTION:
Notice.
The Administration for
Community Living (ACL) announces the
intent to award a single-source
supplement to the current cooperative
agreement held by the University of
Massachusetts for the Alternatives to
Guardianship Youth Resource Center
cooperative agreement. The purpose of
this project is to divert high school
students with intellectual and
developmental disabilities (I/DD) away
from guardianship to less restrictive
decisional supports. The target audience
for this information includes youth with
I/DD, families, and caregivers of high
school students with I/DD, teachers,
education administrators, advocates,
vocational rehabilitation counselors,
guidance counselors, and school district
officials. The administrative supplement
for FY 2023 will amount to $200,000,
bringing the total award for FY 2023 to
$500,000.
FOR FURTHER INFORMATION CONTACT: For
further information or comments
regarding this program supplement,
contact Dana Fink, U.S. Department of
Health and Human Services,
Administration for Community Living,
Administration on Disabilities, (202)
795–7604 or via email dana.fink@
acl.hhs.gov.
SUPPLEMENTARY INFORMATION: This
supplementary funding will expand the
Alternatives to Guardianship Youth
Resource Center’s engagement and
education efforts around diverting high
school students with I/DD away from
guardianship to less restrictive
decisional supports. As a result of
funding this Center, ACL expects that:
• More students with I/DD will have
more decisional options, such as Powers
of Attorney, supported-decision-making,
joint bank accounts, bill paying services,
and medical or educational release
forms, on completion of high school;
• Fewer young adults with I/DD will
be subject to guardianship;
• The public will become more
knowledgeable of alternatives to
guardianship; and
• Youth will become more
independent by gaining job experience
and personal responsibilities.
This supplement will fund:
SUMMARY:
PO 00000
Frm 00044
Fmt 4703
Sfmt 4703
62089
• Support to enhance the engagement
of youth advisory board members,
including (1) a dedicated staff member
for facilitation and administrative
coordination and support and; (2) paid
opportunities for youth advisory board
members to be more deeply engaged in
project activities.
• Continued support for two
additional staff members from grant
partner Self-Advocates Becoming
Empowered who have joined the youth
ambassador training team.
• Additional training for project staff
and partners on allyship and
augmentative and alternative
communication (AAC) to support a state
team of AAC users.
• Support for travel for youth
ambassadors and youth advisors to
participate in conference presentations.
• Supervisory support for the new
youth trainer position that will begin
August 2023. This youth trainer will
join the Youth Ambassador workgroup
and be part of the training team that
facilitates the third cohort of youth
ambassadors from Texas, California, and
New York.
• Continued enhancement to the
project website, which includes a
dedicated page for each of the 40+ youth
ambassadors, youth-friendly products
and videos, and plain language
documents.
The administrative supplement for FY
2023 will amount to $200,000, bringing
the total award for FY 2023 to $500,000.
Program Name: Center for Youth
Voice Youth Choice (CYVYC)
Alternatives to Guardianship Youth
Resource Center.
Recipient: University of
Massachusetts, Boston.
Period of Performance: The
supplement award will be issued for the
fourth year of the five-year project
period of September 1, 2023, through
August 31, 2024.
Total Supplement Award Amount:
$200,000.
Award Type: Cooperative Agreement.
Statutory Authority: This program is
authorized under the Developmental
Disabilities Assistance and Bill of Rights
Act of 2000 Pub. L. 106–402, Section
161(2) (B), (C) and (D).
Basis for Award:
The University of Massachusetts is
currently funded to carry out the
CYVYC Project for the period of
September 1, 2020 through August 31,
2025. Much work has already been
completed and further tasks are
currently being accomplished. It would
be unnecessarily time consuming and
disruptive to the CYVYC project and the
beneficiaries being served for ACL to
establish a new grantee at this time
E:\FR\FM\08SEN1.SGM
08SEN1
62090
Federal Register / Vol. 88, No. 173 / Friday, September 8, 2023 / Notices
when critical services are presently
being provided in an efficient manner.
Dated: September 4, 2023.
Alison Barkoff,
Senior official performing the duties of the
Administrator and the Assistant Secretary for
Aging.
[FR Doc. 2023–19391 Filed 9–7–23; 8:45 am]
BILLING CODE 4154–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA–2023–D–3518]
Endogenous Cushing’s Syndrome:
Developing Drugs for Treatment; Draft
Guidance for Industry; Availability
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
Notice of availability.
The Food and Drug
Administration (FDA or Agency) is
announcing the availability of a draft
guidance for industry entitled
‘‘Endogenous Cushing’s Syndrome:
Developing Drugs for Treatment.’’ The
purpose of this guidance is to provide
recommendations to sponsors regarding
clinical trial designs for drugs intended
for the treatment of adults with
endogenous Cushing’s syndrome for
whom surgery is not an option or has
not been curative. This draft guidance is
intended to focus continued discussions
among FDA’s Division of General
Endocrinology, pharmaceutical
sponsors, the academic community, and
the public.
DATES: Submit either electronic or
written comments on the draft guidance
by November 7, 2023 to ensure that the
Agency considers your comment on this
draft guidance before it begins work on
the final version of the guidance.
ADDRESSES: You may submit comments
on any guidance at any time as follows:
SUMMARY:
lotter on DSK11XQN23PROD with NOTICES1
Electronic Submissions
Submit electronic comments in the
following way:
• Federal eRulemaking Portal:
https://www.regulations.gov. Follow the
instructions for submitting comments.
Comments submitted electronically,
including attachments, to https://
www.regulations.gov will be posted to
the docket unchanged. Because your
comment will be made public, you are
solely responsible for ensuring that your
comment does not include any
confidential information that you or a
third party may not wish to be posted,
such as medical information, your or
VerDate Sep<11>2014
17:30 Sep 07, 2023
Jkt 259001
anyone else’s Social Security number, or
confidential business information, such
as a manufacturing process. Please note
that if you include your name, contact
information, or other information that
identifies you in the body of your
comments, that information will be
posted on https://www.regulations.gov.
• If you want to submit a comment
with confidential information that you
do not wish to be made available to the
public, submit the comment as a
written/paper submission and in the
manner detailed (see ‘‘Written/Paper
Submissions’’ and ‘‘Instructions’’).
Written/Paper Submissions
Submit written/paper submissions as
follows:
• Mail/Hand Delivery/Courier (for
written/paper submissions): Dockets
Management Staff (HFA–305), Food and
Drug Administration, 5630 Fishers
Lane, Rm. 1061, Rockville, MD 20852.
• For written/paper comments
submitted to the Dockets Management
Staff, FDA will post your comment, as
well as any attachments, except for
information submitted, marked and
identified, as confidential, if submitted
as detailed in ‘‘Instructions.’’
Instructions: All submissions received
must include the Docket No. FDA–
2023–D–3518 for ‘‘Endogenous
Cushing’s Syndrome: Developing Drugs
for Treatment.’’ Received comments will
be placed in the docket and, except for
those submitted as ‘‘Confidential
Submissions,’’ publicly viewable at
https://www.regulations.gov or at the
Dockets Management Staff between 9
a.m. and 4 p.m., Monday through
Friday, 240–402–7500.
• Confidential Submissions—To
submit a comment with confidential
information that you do not wish to be
made publicly available, submit your
comments only as a written/paper
submission. You should submit two
copies total. One copy will include the
information you claim to be confidential
with a heading or cover note that states
‘‘THIS DOCUMENT CONTAINS
CONFIDENTIAL INFORMATION.’’ The
Agency will review this copy, including
the claimed confidential information, in
its consideration of comments. The
second copy, which will have the
claimed confidential information
redacted/blacked out, will be available
for public viewing and posted on
https://www.regulations.gov. Submit
both copies to the Dockets Management
Staff. If you do not wish your name and
contact information to be made publicly
available, you can provide this
information on the cover sheet and not
in the body of your comments and you
must identify this information as
PO 00000
Frm 00045
Fmt 4703
Sfmt 4703
‘‘confidential.’’ Any information marked
as ‘‘confidential’’ will not be disclosed
except in accordance with 21 CFR 10.20
and other applicable disclosure law. For
more information about FDA’s posting
of comments to public dockets, see 80
FR 56469, September 18, 2015, or access
the information at: https://
www.govinfo.gov/content/pkg/FR-201509-18/pdf/2015-23389.pdf.
Docket: For access to the docket to
read background documents or the
electronic and written/paper comments
received, go to https://
www.regulations.gov and insert the
docket number, found in brackets in the
heading of this document, into the
‘‘Search’’ box and follow the prompts
and/or go to the Dockets Management
Staff, 5630 Fishers Lane, Rm. 1061,
Rockville, MD 20852, 240–402–7500.
You may submit comments on any
guidance at any time (see 21 CFR
10.115(g)(5)).
Submit written requests for single
copies of the draft guidance to the
Division of Drug Information, Center for
Drug Evaluation and Research, Food
and Drug Administration, 10001 New
Hampshire Ave., Hillandale Building,
4th Floor, Silver Spring, MD 20993–
0002. Send one self-addressed adhesive
label to assist that office in processing
your requests. See the SUPPLEMENTARY
INFORMATION section for electronic
access to the draft guidance document.
FOR FURTHER INFORMATION CONTACT:
Naomi Lowy, Center for Drug
Evaluation and Research, Food and
Drug Administration, 10903 New
Hampshire Ave., Silver Spring, MD
20993, 301–796–0692.
SUPPLEMENTARY INFORMATION:
I. Background
FDA is announcing the availability of
a draft guidance for industry entitled
‘‘Endogenous Cushing’s Syndrome:
Developing Drugs for Treatment.’’ The
purpose of this guidance is to provide
recommendations to sponsors regarding
clinical trial designs for drugs intended
for the treatment of adults with
endogenous Cushing’s syndrome for
whom surgery is not an option or has
not been curative. This draft guidance is
intended to focus continued discussions
among FDA’s Division of General
Endocrinology, pharmaceutical
sponsors, the academic community, and
the public. This is the first guidance
drafted by FDA on this topic.
This draft guidance is being issued
consistent with FDA’s good guidance
practices regulation (21 CFR 10.115).
The draft guidance, when finalized, will
represent the current thinking of FDA
on ‘‘Endogenous Cushing’s Syndrome:
E:\FR\FM\08SEN1.SGM
08SEN1
]]>Agencies
[Federal Register Volume 88, Number 173 (Friday, September 8, 2023)]
[Notices]
[Pages 62089-62090]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2023-19391]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Administration for Community Living
Announcing the Intent To Award a Single-Source Supplement for the
Alternatives to Guardianship Youth Resource Center Cooperative
Agreement
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The Administration for Community Living (ACL) announces the
intent to award a single-source supplement to the current cooperative
agreement held by the University of Massachusetts for the Alternatives
to Guardianship Youth Resource Center cooperative agreement. The
purpose of this project is to divert high school students with
intellectual and developmental disabilities (I/DD) away from
guardianship to less restrictive decisional supports. The target
audience for this information includes youth with I/DD, families, and
caregivers of high school students with I/DD, teachers, education
administrators, advocates, vocational rehabilitation counselors,
guidance counselors, and school district officials. The administrative
supplement for FY 2023 will amount to $200,000, bringing the total
award for FY 2023 to $500,000.
FOR FURTHER INFORMATION CONTACT: For further information or comments
regarding this program supplement, contact Dana Fink, U.S. Department
of Health and Human Services, Administration for Community Living,
Administration on Disabilities, (202) 795-7604 or via email
[email protected].
SUPPLEMENTARY INFORMATION: This supplementary funding will expand the
Alternatives to Guardianship Youth Resource Center's engagement and
education efforts around diverting high school students with I/DD away
from guardianship to less restrictive decisional supports. As a result
of funding this Center, ACL expects that:
More students with I/DD will have more decisional options,
such as Powers of Attorney, supported-decision-making, joint bank
accounts, bill paying services, and medical or educational release
forms, on completion of high school;
Fewer young adults with I/DD will be subject to
guardianship;
The public will become more knowledgeable of alternatives
to guardianship; and
Youth will become more independent by gaining job
experience and personal responsibilities.
This supplement will fund:
Support to enhance the engagement of youth advisory board
members, including (1) a dedicated staff member for facilitation and
administrative coordination and support and; (2) paid opportunities for
youth advisory board members to be more deeply engaged in project
activities.
Continued support for two additional staff members from
grant partner Self-Advocates Becoming Empowered who have joined the
youth ambassador training team.
Additional training for project staff and partners on
allyship and augmentative and alternative communication (AAC) to
support a state team of AAC users.
Support for travel for youth ambassadors and youth
advisors to participate in conference presentations.
Supervisory support for the new youth trainer position
that will begin August 2023. This youth trainer will join the Youth
Ambassador workgroup and be part of the training team that facilitates
the third cohort of youth ambassadors from Texas, California, and New
York.
Continued enhancement to the project website, which
includes a dedicated page for each of the 40+ youth ambassadors, youth-
friendly products and videos, and plain language documents.
The administrative supplement for FY 2023 will amount to $200,000,
bringing the total award for FY 2023 to $500,000.
Program Name: Center for Youth Voice Youth Choice (CYVYC)
Alternatives to Guardianship Youth Resource Center.
Recipient: University of Massachusetts, Boston.
Period of Performance: The supplement award will be issued for the
fourth year of the five-year project period of September 1, 2023,
through August 31, 2024.
Total Supplement Award Amount: $200,000.
Award Type: Cooperative Agreement.
Statutory Authority: This program is authorized under the
Developmental Disabilities Assistance and Bill of Rights Act of 2000
Pub. L. 106-402, Section 161(2) (B), (C) and (D).
Basis for Award:
The University of Massachusetts is currently funded to carry out
the CYVYC Project for the period of September 1, 2020 through August
31, 2025. Much work has already been completed and further tasks are
currently being accomplished. It would be unnecessarily time consuming
and disruptive to the CYVYC project and the beneficiaries being served
for ACL to establish a new grantee at this time
[[Page 62090]]
when critical services are presently being provided in an efficient
manner.
Dated: September 4, 2023.
Alison Barkoff,
Senior official performing the duties of the Administrator and the
Assistant Secretary for Aging.
[FR Doc. 2023-19391 Filed 9-7-23; 8:45 am]
BILLING CODE 4154-01-P
